Table of Contents
  CME Information
  Faculty and Affiliations
  Editor’s Note:
Til death do us part
Neil Love, MD
   
CASE 1:

A 36-year-old woman with a family history of breast cancer and a poorly differentiated, node-negative IDC of the breast who wishes to retain her fertility (from the practice of Dr Richard S Zelkowitz)
CASE 2:

A 48-year-old woman with an ER/PR-negative, HER2-positive invasive ductal carcinoma with 11/16 positive nodes who developed CNS and bone metastases three years after local and adjuvant systemic therapy (from the practice of Dr Leonard J Seigel)
CASE 3:
 A 73-year-old woman with ER/PR-positive, node-positive breast cancer who was switched to exemestane after three years of adjuvant tamoxifen (from the practice of Dr Arnold S Blaustein)
CASE 4:
A woman in her late forties diagnosed with a small, node-negative breast tumor who developed a sternal metastasis after two and one half years of tamoxifen with a shift in tumor phenotype from the primary lesion (from the practice of Dr Lowell L Hart)
CASE 5:
 A 67-year-old woman a large ER/PR-positive, HER2-negative infiltrating ductal carcinoma with two positive lymph nodes (from the practice of Dr Lawrence A Tepper)
CASE 6:
 A 41-year-old woman with an ER/PR-positive, HER2-negative breast tumor who had significant residual disease after AC and docetaxel neoadjuvant therapy (from the practice of Dr Michael S Wertheim)
CASE 7:
 A 72-year-old woman with high-risk, ER/PR-positive breast cancer who refuses treatment with AIs after experiencing uncommon side effects and who subsequently develops a painful metastatic skin nodule and bone metastases (from the practice of Dr David M Dresdner)


2005 VOL 3, ISSUE 2

EDITOR
Neil Love, MD

FACULTY
Howard A Burris III, MD
Nancy E Davidson, MD
Kathy D Miller, MD
Mark D Pegram, MD


CME test online

Editor's Office

Previous issues
Home · Contact Us
Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved